NASDAQ:XOMA

Xoma Stock News

Healthcare > Biotechnology

Buy XOMA

*Your capital is at risk

$41.70

+0.0100 (+0.0240%)

At Close: Jun 03, 2026

XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance

07:30am, Tuesday, 03'rd Nov 2020

EMERYVILLE, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies In

XOMA Earns $25 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer

07:30am, Wednesday, 28'th Oct 2020

EMERYVILLE, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2 developm

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by